EN

Elafibranor (Iqirvo®) Advances to Phase 3 Clinical Trial for PSC

Significant and encouraging clinical trial news in the field of primary sclerosing cholangitis (PSC) drug development. The trial sponsor, Ipsen and developer, GENFIT, announced on Feb. 12, 2026, that elafibranor has progressed to a Phase 3 clinical trial for PSC, known as the ELASCOPE study. Advancing to a Phase 3 trial represents an important milestone … Read more

Updates from AASLD The Liver Meeting® 2025

In November 2025, thousands of global experts gathered for The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), a professional association for doctors, scientists, and healthcare providers focused on preventing, curing, and treating liver diseases. The Liver Meeting® is recognized as the largest gathering of hepatologists and liver … Read more

The Loon Duct newsletter

The Loon Duct – PSC Partners Canada’s Quarterly Newsletter

The Loon Duct e-newsletter helps the PSC Community in Canada stay up to date on upcoming events, research, and other PSC news. Emailed quarterly, the newsletter also highlights people’s stories about their experiences living with PSC. Most Recent Issue: December 2025 In the December 2025 issue of The Loon Duct, read the 2025 Year in Review, … Read more

Test tubes used for PSC research

Funding for Canadian collaborative PSC research team announced

Fantastic news was released today about the Developing Medicines through Open Science program from Canadian organization Conscience which is supporting open science and nonprofit drug development. In honour of the upcoming Rare Disease Day (Feb 28, 2025), today’s grant announcement includes PSC! PSC Partners and PSC Partners Canada are proud to be a part of … Read more